Ljubljana/summary
From 2007.igem.org
Line 90: | Line 90: | ||
<div id="footer">______________________________________<br /> | <div id="footer">______________________________________<br /> | ||
+ | <a href="https://2007.igem.org/Ljubljana/methods">Methods</a> | ||
|<a href="https://2007.igem.org/Ljubljana">Home</a>| | |<a href="https://2007.igem.org/Ljubljana">Home</a>| | ||
- | <a href="https://2007.igem.org/Ljubljana/ | + | <a href="https://2007.igem.org/Ljubljana/team">Team</a> |
</div> | </div> | ||
- | |||
- | |||
</div> | </div> | ||
<div id="linkList"> | <div id="linkList"> | ||
<div id="linkList2"> | <div id="linkList2"> | ||
<div id="lmenu"> | <div id="lmenu"> | ||
+ | |||
+ | <center> | ||
+ | <a href="https://2007.igem.org/Ljubljana"> | ||
+ | <img border="0" src="https://static.igem.org/mediawiki/2007/c/c6/BlurMetalHome.gif" width="34" height="34"> | ||
+ | </center> | ||
+ | |||
+ | |||
+ | |||
<h3 class="menu"><span><a class="two" href="https://2007.igem.org/Ljubljana/AIDSplague">AIDS - Today's Plague</a></span></h3> | <h3 class="menu"><span><a class="two" href="https://2007.igem.org/Ljubljana/AIDSplague">AIDS - Today's Plague</a></span></h3> | ||
<ul> | <ul> | ||
+ | <li><a class="one" href="https://2007.igem.org/Ljubljana/AIDSplague">Epidemics</a> </li> | ||
<li><a class="one" href="https://2007.igem.org/Ljubljana/HIVbacground">HIV-1 Infection Background</a> </li> | <li><a class="one" href="https://2007.igem.org/Ljubljana/HIVbacground">HIV-1 Infection Background</a> </li> | ||
<li><a class="one" href="https://2007.igem.org/Ljubljana/Currenttreatment">Current Disease Treatment</a> </li> | <li><a class="one" href="https://2007.igem.org/Ljubljana/Currenttreatment">Current Disease Treatment</a> </li> | ||
Line 106: | Line 114: | ||
</div> | </div> | ||
<div id="llinks"> | <div id="llinks"> | ||
- | <h3 class="links"><span><a class="two" href="https://2007.igem.org/Ljubljana/Strategy"> | + | <h3 class="links"><span><a class="two" href="https://2007.igem.org/Ljubljana/Strategy">Project</a></span></h3> |
<ul> | <ul> | ||
- | + | <li><a class="one" href="https://2007.igem.org/Ljubljana/Strategy">Strategy</a> </li> | |
+ | <li><a class="one" href="https://2007.igem.org/Ljubljana/implementation">Implementation</a> </li> | ||
<li><a class="one" href="https://2007.igem.org/Ljubljana/model">Model</a> </li> | <li><a class="one" href="https://2007.igem.org/Ljubljana/model">Model</a> </li> | ||
</ul> | </ul> | ||
Line 126: | Line 135: | ||
<ul> | <ul> | ||
- | <li><a class="one" href="https://2007.igem.org/Ljubljana/ | + | <li><a class="one" href="https://2007.igem.org/Ljubljana/summary">Achievements</a> </li> |
- | <li><a class="one" href="https://2007.igem.org/Ljubljana/ | + | <li><a class="one" href="https://2007.igem.org/Ljubljana/summary">Prospects</a> </li> |
Line 135: | Line 144: | ||
<div id="ldiscussion"> | <div id="ldiscussion"> | ||
<h3 class="discussion"><span><a class="two" href="https://2007.igem.org/Ljubljana/team">Team</a></span></h3> | <h3 class="discussion"><span><a class="two" href="https://2007.igem.org/Ljubljana/team">Team</a></span></h3> | ||
- | < | + | <br><br> |
- | + | </div> | |
- | <br>< | + | |
- | <li><a class="one" href="https://2007.igem.org/Ljubljana/glossary">Terms & References</a> </li> | + | <div id="ldiscussion"> |
+ | <ul><li><a class="one" href="https://2007.igem.org/Ljubljana/glossary">Terms & References</a> </li> | ||
<li><a class="one" href="https://2007.igem.org/Ljubljana/acknowledgements">Acknowledgements</a> </li> | <li><a class="one" href="https://2007.igem.org/Ljubljana/acknowledgements">Acknowledgements</a> </li> | ||
</ul> | </ul> |
Revision as of 15:19, 26 October 2007
Achievements
Prospects for future work and real world applications
- The idea of relying on viral functions could be applied also to other HIV-specific processes (such as genome integration, reverse transcription…).
- Our system based on BioBricks has been useful to prove the principle, but for the real application cellular delivery would be much better applied using vectors based on viral delivery.
- In the case of using viral vectors, therapy could be delivered specifically to the relevant cells that can be infected by HIV-1 (e.g. similar as T-cell-directed retroviral delivery systems described by David Baltimore at SB2.0).
- Selection of different effectors will (and can) be made based on further experiments – apoptosis can only be used in 100% leak-proof systems, while antiviral and immune response effectors are not as sensitive.
- Similar systems can be prepared for therapy of many other pathogens, particularly viruses (e.g. yellow fever, SARS, foot and mouth disease…) which contain specific proteases and rely on defined cellular receptors.